SAN FRANCISCO (Thomson Financial) - Theravance Inc. late Thursday reported a
net loss of $33.1 million, or 54 cents a share, versus the mean 55-cent loss
estimate of analysts polled by Thomson Financial.
The net loss a year earlier was $37.8 million, or 63 cents a share.
The South San Francisco, Calif.-based biopharmaceutical company said revenue
rose to $5.63 million from $4.93 million a year earlier, versus the mean analyst
estimate of $8.65 million.
The stock fell 61 cents to close at $17.49.
Brigid Gaffikin
bg/gm
COPYRIGHT
Copyright Thomson Financial News Limited 2007. All rights reserved.
The copying, republication or redistribution of Thomson Financial News Content,
including by framing or similar means, is expressly prohibited without the prior
written consent of Thomson Financial News.
|